Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18950649 | BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELS | November 2024 | February 2025 | Allow | 3 | 1 | 0 | No | No |
| 18363526 | CORE-SHELL MICRONEEDLE PATCH FOR H2O2 AND PH CASCADE-TRIGGERED INSULIN DELIVERY | August 2023 | January 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18225227 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY | July 2023 | January 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18317436 | MODULATION OF SOLUBILITY, PALATABILITY, ABSORPTION, AND BIOAVAILABILITY OF MITRAGYNA SPECIOSA-DERIVED COMPOUNDS FOR ORAL AND BUCCAL DELIVERY | May 2023 | July 2024 | Abandon | 15 | 2 | 0 | No | No |
| 18108038 | METHOD OF MAKING AN OSTEOCONDUCTIVE FIBROUS ARTICLE AND A MEDICAL IMPLANT COMPRISING SUCH OSTEOCONDUCTIVE FIBROUS ARTICLE | February 2023 | July 2024 | Allow | 17 | 2 | 0 | Yes | No |
| 18093240 | DEPOT FORMULATIONS | January 2023 | November 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17882552 | DRUG DELIVERY METHODS, STRUCTURES, AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM | August 2022 | April 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17750865 | TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF | May 2022 | February 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17724378 | COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND | April 2022 | January 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17716443 | SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCE | April 2022 | January 2025 | Abandon | 34 | 2 | 0 | No | No |
| 17706869 | TOPICAL PAIN PATCH | March 2022 | January 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17698451 | HIGH-CONCENTRATION FLUENSULFONE FORMULATIONS, THEIR USES AND PROCESSES OF PREPARATION | March 2022 | October 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17698389 | Curcumin Solubilisate | March 2022 | January 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17693904 | POROUS BIOCOMPATIBLE IMPLANT WITH EXCELLENT OSSEOINTEGRATION AND METHOD FOR MANUFACTURING SAME | March 2022 | November 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17690837 | METHODS FOR RELIEVING BACK PAIN WITH TERMINALIA CHEBULA COMPOSITIONS | March 2022 | September 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17687534 | METHODS OF USING RIFAMYCIN SV FOR THE TREATMENT OF SICKLE CELL DISEASE | March 2022 | November 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17672651 | ANTIBACTERIAL OR ANTIFUNGAL COMPOSITION | February 2022 | January 2025 | Allow | 35 | 3 | 0 | No | No |
| 17587170 | INHALATION OF NITRIC OXIDE | January 2022 | October 2024 | Abandon | 33 | 2 | 0 | No | No |
| 17581820 | Collagen Membrane or Matrix with Antimicrobial Properties | January 2022 | November 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17627474 | COMPOSITION AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS | January 2022 | May 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17626741 | ORAL DISODIUM PYROPHOSPHATE FOR USE IN REDUCING CALCIFICATION | January 2022 | December 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17569586 | Compositions and Methods for Treating a Disorder or Defect in Soft Tissue | January 2022 | October 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17596945 | BEVERAGE FORTIFIED WITH FERROUS BISGLYCINATE | December 2021 | February 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17596946 | BEVERAGE FORTIFIED WITH FERROUS BISGLYCINATE | December 2021 | February 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17620571 | CONSTITUENT FOR PREVENTING AND/OR TREATING SKIN WOUNDS | December 2021 | December 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17553605 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation | December 2021 | December 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17545588 | CRACKLING HAND SANITIZER FORMULATIONS AND ASSOCIATED METHODS | December 2021 | March 2024 | Abandon | 27 | 2 | 0 | Yes | No |
| 17616633 | NON-NATURAL INSECT PHEROMONE BLEND COMPOSITIONS | December 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17615940 | BIOTHERAPY FOR VIRAL INFECTIONS USING BIOPOLYMER BASED MICRO/NANOGELS | December 2021 | October 2024 | Allow | 34 | 3 | 1 | Yes | No |
| 17614386 | GLYCEROL AND SODIUM PENTABORATE BASED FORMULATION PREVENTING POSTOPERATIVE ADHESIONS | November 2021 | November 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17611975 | Use of metal ions to potentiate the therapeutic effects of arsenic | November 2021 | April 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17527465 | Cannabinoid Emulsifier | November 2021 | September 2024 | Allow | 34 | 3 | 1 | Yes | No |
| 17610734 | AQUEOUS LIQUID COSMETIC | November 2021 | December 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17496515 | BIODEGRADABLE CHITOSAN MICRONEEDLE PATCH FOR TRANSDERMAL DELIVERY FOR LIVESTOCK PAIN MANAGEMENT | October 2021 | June 2025 | Abandon | 44 | 4 | 0 | No | No |
| 17490190 | ANTIBACTERIAL ANTIVIRAL TREATED FABRICS | September 2021 | December 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17488787 | CAPSULE WITH INTERNAL DIAPHRAGM FOR IMPROVED BIOAVAILABILITY | September 2021 | April 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17399709 | COMPOSITIONS COMPRISING DEAD SEA WATER AND POLYSACCHARIDES AND USES THEREOF AS SKIN PROTECTANTS | August 2021 | February 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17398173 | METHOD FOR TREATING CARDIAC CONDITIONS WITH PLACENTA-DERVIVED COMPOSITIONS | August 2021 | June 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17428685 | PHOTO-PROTECTIVE PLANT-DERIVED COMPOSITION | August 2021 | September 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17428334 | IMPROVED ENDOSCOPE DISINFECTANT | August 2021 | June 2025 | Allow | 46 | 7 | 0 | Yes | No |
| 17389719 | DIETARY MACRO/MICRONUTRITIONAL SUPPLEMENT FOR PATIENTS UNDERGOING KIDNEY DIALYSIS | July 2021 | July 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17384145 | ANTITHROMBOTIC COATING COMPOSITION AND ANTITHROMBOTIC COATING METHOD USING SAME | July 2021 | September 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17384198 | ANTIMICROBIAL COATING COMPOSITION AND ANTIMICROBIAL COATING METHOD USING SAME | July 2021 | September 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17367254 | Novel Isoquinoline Derivative, Preparing Method Thereof, and Pharmaceutical Composition for Preventing or Treating Autophagy Related Diseases Containing the Same as an Active Ingredient | July 2021 | February 2023 | Allow | 19 | 1 | 1 | No | No |
| 17416851 | SPRAYING AGENT COMPRISING PESTICIDE | June 2021 | December 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17343169 | PROCESS FOR MANUFACTURING PHENYLEPHRINE RESINATE PARTICLES; PHENYLEPHRINE RESINATE PARTICLES; AND USE OF PHENYLEPHRINE RESINATE PARTICLES IN PHARMACEUTICAL FORMULATIONS | June 2021 | September 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17292536 | UMECLIDINIUM AND VILANTEROL FORMULATION AND INHALER | May 2021 | June 2025 | Abandon | 50 | 2 | 0 | No | Yes |
| 17306053 | SURGICAL SYSTEM AND METHODS OF USE | May 2021 | September 2024 | Allow | 41 | 2 | 0 | Yes | No |
| 17290212 | COMPOSITION OF ACTIVE INGREDIENTS AS BOOSTER FOR UV-FILTERS | April 2021 | June 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17282332 | METHOD AND COMPOSITION FOR RELIEVING FATIGUE AND RESTORING ENERGY | April 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17218960 | COSMETIC COMPOSITION WITH GLAUCINE, RETINOL AND PEPTIDES TO COMBAT SKIN AGING | March 2021 | October 2024 | Abandon | 42 | 4 | 0 | Yes | No |
| 17279886 | TITANIUM DIOXIDE DISPERSION | March 2021 | January 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17210747 | COMPOSITIONS COMPRISING CARUM CARVI AND ROSMARINUS OFFICINALIS EXTRACTS AND METHODS OF USING SAME | March 2021 | April 2025 | Abandon | 48 | 4 | 0 | No | No |
| 17209645 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE BY CONTACT LENS MEDIATED DRUG DELIVERY | March 2021 | November 2023 | Abandon | 31 | 2 | 0 | No | No |
| 17208381 | Compositions and Methods for Treatment of Ocular Conditions | March 2021 | January 2025 | Abandon | 46 | 4 | 1 | Yes | No |
| 17207337 | DEVICE AND METHOD FOR TREATING INFECTIONS | March 2021 | September 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17205630 | TENT WITH ANTIMICROBIAL TREATMENT APPLIED THERETO AND METHOD OF IMPARTING ANTIMICROBIAL PROPERTIES TO THE TENT | March 2021 | December 2023 | Abandon | 33 | 3 | 0 | No | No |
| 17198211 | BIOMIMETIC ELECTRICALLY CONDUCTIVE HYALURONIC ACID-BASED HYDROGELS | March 2021 | October 2023 | Allow | 31 | 2 | 1 | No | No |
| 17196953 | IMPLANTABLE SUSTAINED RELEASE DEVICE AND A METHOD OF USE THEREFOR IN THE TREATMENT OF BRAIN DISORDERS | March 2021 | November 2023 | Allow | 32 | 1 | 1 | Yes | No |
| 17180161 | Kill and Protect Surface Disinfectant and Hand Sanitizer for Combatting Contact Infection Spread | February 2021 | June 2024 | Abandon | 40 | 2 | 0 | Yes | Yes |
| 17179078 | Isoproterenol Compositions and Methods | February 2021 | July 2023 | Allow | 28 | 5 | 0 | Yes | Yes |
| 17175172 | METHODS OF TREATMENT WITH BUPRENORPHINE | February 2021 | March 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17174107 | METHOD OF WEIGHT REGULATION USING NEBULIZED NICOTINE | February 2021 | April 2024 | Abandon | 38 | 2 | 0 | No | No |
| 17156892 | PREPARATION CONTAINING 6,7-UNSATURATED-7-CARBAMOYL MORPHINAN DERIVATIVES | January 2021 | April 2025 | Allow | 51 | 5 | 0 | Yes | No |
| 17150246 | CHEMICAL VAPOR DEPOSITION OF POLYMER COATINGS FOR CONTROLLED DRUG RELEASE, ASSEMBLIES CONTAINING SAME, AND METHODS OF PRODUCTION AND USE THEREOF | January 2021 | November 2023 | Abandon | 34 | 2 | 0 | No | No |
| 17145056 | INHIBITION OF CANDIDA AURIS BIOFILM FORMATION ON MEDICAL AND ENVIRONMENTAL SURFACES BY SILVER NANOPARTICLES | January 2021 | May 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17142725 | SURGICAL SYSTEM AND METHODS OF USE | January 2021 | May 2024 | Abandon | 40 | 4 | 0 | Yes | No |
| 17141609 | ZN-GA SERIES ALLOY AND ITS PREPARATION METHOD AND APPLICATION | January 2021 | May 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17107544 | HYDROGEL/NANOPARTICLE COMPLEX WITH TEMPERATURE SOL-GEL TRANSITION FOR SUSTAINED DRUG RELEASE | November 2020 | May 2024 | Abandon | 41 | 3 | 1 | No | No |
| 17056602 | ANTIMICROBIAL COMPOSITION BASED ON POLYPHENOLS AND POLYSACCHARIDES, METHOD FOR PREPARING THEREOF AND USE OF THE SAME | November 2020 | April 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17053870 | DEPOT ADMINISTRATION OF ILOPERIDONE | November 2020 | May 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17050230 | TETRABENAZINE TRANSDERMAL DELIVERY DEVICE | October 2020 | July 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17069587 | CONDUCTIVE POLYMER MICRONEEDLE ARRAYS FOR ELECTRONICALLY-CONTROLLED DRUG RELEASE | October 2020 | November 2022 | Allow | 25 | 0 | 1 | Yes | No |
| 17063095 | DEPOT FORMULATIONS | October 2020 | April 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17044920 | ASMT EXPRESSION PROMOTER | October 2020 | December 2022 | Abandon | 26 | 1 | 0 | No | No |
| 16971489 | COATINGS FOR IMPLANTABLE DEVICES | August 2020 | January 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 16997894 | Nanoemulsion Compositions Comprising Saponins for Increasing Bioavailability | August 2020 | August 2024 | Abandon | 48 | 3 | 1 | No | No |
| 16963387 | COMPOSITIONS AND METHODS RELATING TO AMNION | July 2020 | June 2025 | Abandon | 59 | 4 | 1 | No | No |
| 16962009 | ELECTROSPUN-COATED MEDICAL DEVICES | July 2020 | August 2024 | Abandon | 50 | 5 | 0 | No | No |
| 16923495 | Post-Charging Of Zeolite Doped Plastics With Antimicrobial Metal Ions | July 2020 | March 2022 | Abandon | 20 | 1 | 0 | No | No |
| 16923486 | Post-Charging Of Zeolite Doped Plastics With Antimicrobial Metal Ions | July 2020 | March 2022 | Abandon | 20 | 1 | 0 | No | No |
| 16960524 | DEVICES, SYSTEMS, AND METHODS FOR TREATING INTRALUMINAL CANCER VIA CONTROLLED DELIVERY OF THERAPEUTIC AGENTS | July 2020 | March 2025 | Allow | 56 | 5 | 0 | Yes | No |
| 16915688 | Subcutaneous Biodegradable Naltrexone Implant And Accompanying Behavioral Program For Weight Loss In A Patient | June 2020 | February 2024 | Abandon | 43 | 4 | 0 | No | No |
| 16888665 | HAIR CARE SYSTEMS AND METHODS FOR DELIVERY OF CUSTOMIZED HAIR CARE PRODUCTS | May 2020 | May 2025 | Abandon | 59 | 4 | 1 | Yes | No |
| 16888015 | DETOXIFICATION AND STABILIZATION OF IMPLANTABLE OR TRANSPLANTABLE BIOLOGICAL MATERIAL | May 2020 | April 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16768544 | MUCOADHESIVE NANOPARTICLE ENTRAPPED INFLUENZA VIRUS VACCINE DELIVERY SYSTEM | May 2020 | December 2023 | Abandon | 42 | 4 | 1 | No | No |
| 16888585 | CARBON QUANTUM DOTS AND PREPARATION PROCESS AND USE THEREOF | May 2020 | September 2021 | Allow | 16 | 0 | 0 | Yes | No |
| 16882815 | Applying Fluoride for Treating or Preventing Viral Infection Including SARS-CoV-2 | May 2020 | June 2022 | Abandon | 24 | 2 | 1 | No | Yes |
| 16765425 | KIT FOR PRODUCING A BODY CARE COMPOSITION | May 2020 | March 2023 | Abandon | 34 | 4 | 0 | No | No |
| 16877055 | BRANCHED SATURATED HYDROCARBON COSMETIC INGREDIENT | May 2020 | September 2022 | Allow | 28 | 2 | 0 | Yes | No |
| 16863935 | INHALATION OF NITRIC OXIDE | April 2020 | February 2022 | Abandon | 21 | 2 | 1 | No | No |
| 16852025 | CATMINT OIL REPELLENT AGAINST MOSQUITOS | April 2020 | February 2024 | Abandon | 46 | 5 | 1 | No | No |
| 16847275 | HARD SURFACE CLEANING SOLUTION WITH RAPID VIRICIDAL ACTIVITY | April 2020 | February 2025 | Allow | 58 | 8 | 0 | Yes | No |
| 16755191 | CORE-SHELL MICRONEEDLE PATCH FOR H2O2 AND PH CASCADE-TRIGGERED INSULIN DELIVERY | April 2020 | April 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16753355 | METHOD OF MAKING AN OSTEOCONDUCTIVE FIBROUS ARTICLE AND A MEDICAL IMPLANT COMPRISING SUCH OSTEOCONDUCTIVE FIBROUS ARTICLE | April 2020 | February 2024 | Allow | 46 | 4 | 1 | Yes | No |
| 16753740 | NEW POLYMERIC EMULSIFIER AND USES THEREOF FOR THE ENCAPSULATION OF HYDROPHOBIC OR HYDROPHILIC ACTIVE COMPOUNDS | April 2020 | May 2023 | Abandon | 37 | 2 | 1 | No | No |
| 16826043 | Implantable Drug Delivery Devices for Localized Drug Delivery | March 2020 | July 2021 | Allow | 16 | 1 | 0 | Yes | Yes |
| 16826022 | IMPLANTABLE DRUG DELIVERY DEVICES FOR LOCALIZED DRUG DELIVERY | March 2020 | February 2022 | Allow | 23 | 2 | 0 | Yes | Yes |
| 16826064 | Implantable Drug Delivery Devices for Localized Drug Delivery | March 2020 | February 2022 | Allow | 23 | 2 | 0 | Yes | Yes |
| 16820826 | TUNABLE NONFOULING SURFACE OF OLIGOETHYLENE GLYCOL | March 2020 | September 2022 | Abandon | 30 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HELM, CARALYNNE E.
With a 12.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HELM, CARALYNNE E works in Art Unit 1615 and has examined 775 patent applications in our dataset. With an allowance rate of 29.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner HELM, CARALYNNE E's allowance rate of 29.8% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HELM, CARALYNNE E receive 2.82 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by HELM, CARALYNNE E is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +53.4% benefit to allowance rate for applications examined by HELM, CARALYNNE E. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 11.3% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 17.4% of cases where such amendments are filed. This entry rate is in the 13% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 55.6% of appeals filed. This is in the 22% percentile among all examiners. Of these withdrawals, 52.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 51.5% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 70% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.6% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.